Table 2.
Phase III trials of somatostatin analogs and molecular targeting therapy in advanced NETs.
| Tumor type and treatment regimen | Patients (number) | ORR (%) | Median PFS (months) | Median TTP (months) | Criteria |
|---|---|---|---|---|---|
| Pancreatic NETs | |||||
| Raymond et al. [71] | RECIST | ||||
| Sunitinib | 86 | 9 | 11.4 | ||
| Placebo | 8 | 0 | 5.5 | ||
| Yao et al. [72] (RADIANT-3 study) | RECIST | ||||
| Everolimus | 207 | 11.0 | |||
| Placebo | 203 | 4.6 | |||
| Small bowel NETs | |||||
| Rinke et al. [65] (PROMID study) | WHO | ||||
| Octreotide LAR | 42 | 2 | 14.3 | ||
| Placebo | 43 | 2 | 6.0 | ||
| Pavel et al. [73] (RADIANT-2 study) | RECIST | ||||
| Everolimus + octreotide LAR | 211 | 16.4 | |||
| Placebo + octreotide LAR | 204 | 11.3 | |||
| Small bowel and pancreatic NETs | |||||
| Caplin et al. [62] (CLARINET study) | RECIST | ||||
| Lanreotide autogel | 101 | Not achieved | |||
| Placebo | 103 | 18.0 | |||
| Small bowel and lung NETs | |||||
| Yao et al. [74] (RADIANT-4 study) | RECIST | ||||
| Everolimus | 205 | 11.0 | |||
| Placebo | 97 | 3.9 |
ORR, overall response rate; PFS, progression-free survival; TTP, time to progression; RECIST, Response Evaluation Criteria in Solid Tumors; LAR, long-acting release; WHO, World Health Organization tumor response criteria.